Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-Mediated Diseases

Novartis will pay $120 million upfront to Monte Rosa for immune disease drug development, with potential total payments reaching $5.7 billion based on milestones and royalties.

Summary by Globe Newswire
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases ...

8 Articles

PharmaphorumPharmaphorum
Center

Novartis agrees $5.7bn degrader deal with Monte Rosa

Novartis has signed its second multibillion-dollar licensing deal with molecular glue degrader specialist Monte Rosa in less than a year

Read Full Article
Globe NewswireGlobe Newswire
Center

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases ...

Read Full Article
biopharmadive.combiopharmadive.com
Center

Novartis dives deeper into protein degraders with second Monte Rosa deal

The company’s new partnership with the "molecular glue” drug developer is broad, focused on immunology and could be worth up to $5.7 billion.

Read Full Article
Cryptocurrency News | Cryptocurrency Prices | Market CapCryptocurrency News | Cryptocurrency Prices | Market Cap

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments

Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments.This article …

Read Full Article
BizTocBizToc

Novartis assembles 2nd molecular glue deal with Monte Rosa, this one worth up to $5.7B

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Read Full Article
pme.chpme.ch

Novartis Reserves Options with American Monte Rosa

American biotech company Monte Rosa Therapeutics has entered into a research agreement with Novartis on immune diseases. The Boston-based laboratory could receive up to $5.7 billion, in addition to an initial payment of $120 million.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Monday, September 15, 2025.
Sources are mostly out of (0)

Similar News Topics

Stock Markets icon

Stock Markets

Technology icon

Technology

News
For You
SearchBlindspotLocal